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EMCDDA–Europol Joint Report on a new 
psychoactive substance: 4,4′-DMAR (4-methyl-5-
(4-methylphenyl)-4,5-dihydrooxazol-2-amine)
In accordance with Article 5 of Council Decision 2005/387/JHA 
on the information exchange, risk assessment and control of 
new psychoactive substances
About this series
EMCDDA–Europol Joint Report publications examine the detailed information 
provided by the EU Member States on individual new psychoactive substances. 
Information is collected from the Reitox network, the Europol national units and the 
national competent authorities of the European Medicines Agency. 
Each Joint Report serves as the basis upon which the decision to conduct a risk 
assessment of the new psychoactive substance is taken. It is part of the three-step 
procedure involving information exchange, risk assessment and decision-making in the 
framework of Council Decision 2005/387/JHA.
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I 1. Introduction
Article 5.1 of Council Decision 2005/387/JHA (1) (hereinafter 
referred to as ‘the Council Decision’) stipulates that ‘Where 
Europol and the EMCDDA, or the Council, acting by a majority 
of its members, consider that the information provided by the 
Member State on a new psychoactive substance merits the 
collection of further information, this information shall be 
collated and presented by Europol and the EMCDDA in the 
form of a Joint Report (hereinafter the “Joint Report”).’ The 
Joint Report shall be submitted to the Council, the European 
Medicines Agency (EMA) and the European Commission.
In February 2014 the European Monitoring Centre for Drugs 
and Drug Addiction (EMCDDA) and Europol examined the 
available information on a new psychoactive substance, 
4-methyl-5-(4-methylphenyl)-4,5-dihydrooxazol-2-amine, 
commonly known by the abbreviation 4,4′-DMAR (2), through a 
joint assessment based upon the following criteria:
1. the amount of the material seized;
2. evidence of organised crime involvement;
3. evidence of international trafficking;
4. analogy with better-studied compounds;
5. evidence of the potential for further (rapid) spread; and,
6. evidence of cases of serious intoxication or fatalities.
The EMCDDA and Europol agreed that the information collected 
on 4,4′-DMAR satisfied criteria 4, 5 and 6. The two organisations 
therefore concluded that sufficient information had been 
accumulated to merit the production of a Joint Report on 
4,4′-DMAR as stipulated by Article 5.1 of the Council Decision.
I 2. Information collection process
In compliance with the provisions of the Council Decision, on 
27 February 2014 the EMCDDA and Europol launched a 
procedure for the collection of information on 4,4′-DMAR, in 
order to prepare the Joint Report. The information was 
collected mainly through the Reitox national focal points in the 
Member States, Turkey and Norway as well as the Europol 
National Units. In addition, the EMA collected information 
through the national competent authorities responsible for 
human and veterinary medicinal products in the Member 
States, Norway, Iceland and Liechtenstein. The information 
collection process was largely concluded by 11 April 2014; 
additional information and clarifications from some countries 
were received up to four weeks after this date.
(1)  OJ L 127, 20.5.2005, p. 32.
(2)  4,4′-DMAR is an abbreviation of 4,4′-dimethylaminorex.
Europol asked the Europol National Units to provide 
information on:
n  the level of 4,4′-DMAR production in their country;
n  the level of 4,4′-DMAR distribution in their country;
n  the level of 4,4′-DMAR trafficking in their country, for 
internal, transit or export purposes;
n  the number of seizures of 4,4′-DMAR in their country, the 
total amount of the seizures, country of origin, details on 
the physical forms (including photos);
n  the role of organised crime, or criminal groups, in the 
production, distribution and trafficking of 4,4′-DMAR in 
their country; and,
n  any known aspect of violence and/or money laundering 
relating to the production and trafficking of 4,4′-DMAR.
Europol received responses from 22 Member States.
According to Article 5.3 of the Council Decision, the EMA 
requested the national competent authorities responsible for 
human and veterinary medicinal products in the Member 
States, Norway, Iceland and Liechtenstein to provide 
information on whether:
n  the new psychoactive substance 4,4′-DMAR has obtained 
a marketing authorisation;
n  the new psychoactive substance 4,4′-DMAR is the subject 
of an application for a marketing authorisation; and,
n  a marketing authorisation that had been granted in respect 
of the new psychoactive substance 4,4′-DMAR has been 
suspended.
The EMA received responses from 21 Member States (3), 
Norway and Iceland. The EMA also provided information as 
relevant to the central authorisation procedure.
Furthermore, in anticipation of Article 7.3 of the Council 
Decision in relation to the manufacturing of medicinal 
products in the European Union, the EMA also requested 
information on whether the new psychoactive substance 
4,4′-DMAR is used to manufacture a medicinal product:
n  which has been granted a marketing authorisation;
n  for which an application has been made for a marketing 
authorisation; and,
n  for which a marketing authorisation has been suspended 
by a competent authority.
(3)  Austria, Belgium, Croatia, the Czech Republic, Denmark, Estonia, Finland, 
France, Germany, Hungary, Ireland, Italy, Latvia, Lithuania, the Netherlands, 
Poland, Portugal, Slovenia, Spain, Sweden and the United Kingdom.
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The EMA received responses from 21 Member States (3), 
Norway and Iceland. The EMA also provided information as 
relevant to the central authorisation procedure.
The EMCDDA collected data through:
1.  a structured questionnaire from the Reitox national focal 
points. The EMCDDA received replies from all Member 
States, Turkey and Norway;
2.  data previously provided to the European Union Early 
Warning System (hereafter ‘Early Warning System’) 
through EMCDDA–Europol Reporting Forms, EWS 
Progress and Final Reports; 
3.  a specific information request to the World Health 
Organization on whether or not 4,4′-DMAR is under 
assessment by the United Nations system (see section 
3.5);
4.  a structured search of the medical and scientific literature 
(hereafter ‘literature’) and Internet suppliers/retailers of 
new psychoactive substances;
5.  a search of relevant Internet drug discussion forums and 
related websites (hereafter, ‘user websites’).
Thus, information included in sections 3.2.1 and 3.3 of the 
Joint Report was provided by Europol, while the EMCDDA 
provided information included in sections 3.1, 3.2.2, 3.4, 3.5, 
3.6, 3.7, 3.8.1, 3.8.2 and 3.8.3 (in part). The information 
included in sections 3.8.3 (in part), 4.1, 4.2 and 4.3 was 
provided by the EMA. The conclusion of the Joint Report was 
prepared and agreed by the two organisations responsible — 
the EMCDDA and Europol. Further details of the seizures and 
collected samples (including images where available) reported 
to the EMCDDA and Europol are provided in Annex 1. The 
details of deaths associated with 4,4′-DMAR that have been 
reported to the EMCDDA are provided in Annex 2.
I 3.  Information required by Article 5.2 of the Council Decision
The order and titles of subsections 3.1 to 3.8 and section 4 
below are as they appear in Article 5.2(a) to (h) and Article 
5.3(a) to (c) of the Council Decision; all sections are cross-
referenced with those set down in the Council Decision.
I 3.1.  Chemical and physical description, including the names under which the new psychoactive substance is known — Article 5.2(a) of the Council Decision
Chemical description and names
4,4′-DMAR is a di-substituted 2-amino-5-phenyl oxazoline 
substance, substituted with a methyl group both at the 4 
position on the phenyl ring and the oxazoline ring. It is a 
derivative of aminorex and 4-methylaminorex (4-MAR), both 
synthetic stimulants which are controlled under the 1971 
United Nations Convention on Psychotropic Substances; 
4-MAR is listed in Schedule I and aminorex is listed in 
Schedule IV. The structures of 4,4′-DMAR, 4-MAR and 
aminorex are provided in Figure 1. 
FIGURE 1
The numbered molecular structure, formula, weight and monoisotopic mass of 4,4′-DMAR.  
The molecular structures of 4-MAR and aminorex are provided for comparison.
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The IUPAC name for 4,4′-DMAR is: 4-methyl-5-(4-
methylphenyl)-4,5-dihydrooxazol-2-amine. 
Additional chemical names have been reported:
4,5-dihydro-4-methyl-5-(4-methylphenyl)-2-oxazolamine
4-methyl-5-(4-methylphenyl)-4,5-dihydro-1,3-oxazol-2-amine
Common names or codenames have also been reported: 
para-methyl-4-methylaminorex;
p-methyl-4-methylaminorex;
4-methylaminorex p-methyl derivative; 
4,4′-dimethylaminorex; 
p4-DMAR; 
4-methyl-euphoria;
4-methyl-U4Euh; 
4-M-4-MAR; 
Serotoni; 
ST.
The ‘euphoria’ or ‘U4Euh’ component of these names refers to 
a slang term for the stimulant 4-MAR (Figure 1), which was a 
‘designer drug’ that appeared in the 1980s as a street drug 
(Davis et al., 1988; Klein et al., 1989).
Chemical Abstract Service (CAS) registry numbers
1445569-01-6 form not specified
364064-08-4  free base of the (4S,5S)-enantiomer
No further CAS registry numbers were identified at this stage.
The REACH registered substances database hosted by the 
European Chemicals Agency (ECHA) was searched using the 
CAS registry numbers listed above. The search returned no 
results.
Physical description
The hydrochloride salt form of 4,4′-DMAR is a crystalline solid 
at room temperature.
Information provided from seizures and a collected sample 
have noted the presence of 4,4′-DMAR in powders and tablets.
The (±)-cis racemate was characterised in the collected 
sample that was reported by the United Kingdom. No 
information was provided on the chemical form present in the 
other detections of the substance reported by the Member 
States.
A more detailed description of 4,4′-DMAR seizures and 
collected samples encountered can be found in subsections 
3.2.1 and 3.2.2 below. Images of seizures and collected 
samples are provided in Annex 1.
I
 3.2.  Information on the frequency, circumstances 
and/or quantities in which a new psychoactive 
substance is encountered, and information on 
the means and methods of manufacture of the 
new psychoactive substance — Article 5.2(b) of 
the Council Decision
3.2.1. Information provided to Europol
Europol received replies from 22 Member States (Austria, 
Belgium, Bulgaria, Croatia, Cyprus, the Czech Republic, 
Estonia, Finland, France, Germany, Hungary, Italy, Latvia, 
Lithuania, Luxembourg, the Netherlands, Portugal, Romania, 
Slovakia, Slovenia, Spain and Sweden). Of these, 18 countries 
had no data relating to 4,4′-DMAR (Austria, Belgium, Bulgaria, 
Croatia, Cyprus, the Czech Republic, Estonia, France, 
Germany, Italy, Latvia, Lithuania, Luxembourg, Portugal, 
Slovakia, Slovenia, Spain and Sweden). The remaining four 
countries (Finland, Hungary, the Netherlands and Romania) 
reported the following information.
The level of production, distribution and trafficking
Finland reported a small seizure that took place on 23 May 
2013. It was a confiscation of two tablets containing 4,4′-
DMAR, made by customs authorities in Helsinki, in a parcel 
coming from the United Kingdom. This seizure was reported 
by the Finnish national focal point to the EMCDDA on 2 July 
2013 (see section 3.2.2 below). 
Hungary reported that 4,4′-DMAR had been used to make 
tablets, and that this tableting was presumably done in 
Hungary. No further details were provided. 
Hungary provided data revealing a significant number of 
seizures where 4,4′-DMAR had been identified. According to 
this information, between June and October 2013 the 
Hungarian authorities recorded 78 seizures of 4,4′-DMAR. The 
Hungarian national focal point also reported these seizures to 
the EMCDDA (see section 3.2.2 below). This is a clear 
indication of the wide availability of this substance in the 
Hungarian drug market. According to the Hungarian 
information, the substance was mainly shipped from China. In 
a significant majority of the recorded seizures, 4,4′-DMAR was 
identified on its own. There have been also seizures, both in 
powder and tablet form, when the substance was seized as a 
mixture with other new psychoactive substances 
(predominantly cathinones) such as pentedrone, 
methcathinone, MPPP, alpha-PVP, bk-MPA, PVP and 
JOINT REPORTS I 4,4′-DMAR
6 / 20
mephedrone, and also in combination with UR-144, RH-34 and 
5-APDB.
As already mentioned, 4,4′-DMAR was seized either in powder 
or in tablet form. Seizures in powder ranged from 0.01 g to 
192.87 g. In the majority of cases, the powder was white; 
however, pink, green and blue powder has also been reported. 
In relation to tablets, they have been reported in different 
colours and as specific shapes or specific pressed logos, such 
as: ‘Playboy’, ‘Heart’, ‘Mitsubishi’, ‘Star’ and ‘Transformers’ (see 
Annex 1). According to Hungarian authorities, the number of 
seizures related to 4,4′-DMAR significantly decreased after the 
introduction of control measures. 
The Netherlands reported only one incident where 4,4′-DMAR 
was detected. It was a shipment of a parcel containing 500 g 
of pale yellow powder. The package was sent from India and 
was destined for a well-known wholesaler of new 
psychoactive substances in the Netherlands. On the shipping 
documents, the substance was declared as: 4,5-DYHYDRO-4-
METHYL-5(-4-METHYLPHENYL)-2-OXAZOLAM (the correct 
chemical name for 4,4′-DMAR, apart from the three missing 
final letters ‘INE’). Due to current legislation in the 
Netherlands, it is not possible to seize new psychoactive 
substances that are not controlled. The Netherlands national 
focal point reported this detection to the EMCDDA on 10 
December 2012 (see section 3.2.2 below).
Romania reported 14 seizures where 4,4′-DMAR was 
identified. In 13 cases the substance was seized as white 
powder totalling 564.23 g. In the other incident five tablets 
containing 4,4′-DMAR were seized. It was also stated that in all 
cases the substance was shipped from abroad and intended 
for so-called ‘own consumption’. No further details were 
provided. The Romanian national focal point also reported 13 
of these seizures to the EMCDDA (see section 3.2.2 below).
No reports were received that indicated licit or illicit 
production of 4,4′-DMAR in any Member States. However, the 
Netherlands reported an incident from 2009 related to the 
production of 4-MAR, which is closely related to 4,4′-DMAR. 
The case involved the discovery of an illicit production site. The 
forensic examination conducted by the Netherlands Forensic 
Institute demonstrated that both MDMA via the bromosafrole 
route and PMK (4) via the Wacker method were produced in 
this illicit laboratory. Moreover, several different types of 
substances, chemicals and recipes were found. It was 
suggested that it was a so-called ‘experimental type’ illicit 
laboratory. Two white plastic trays were found containing a 
few hundred grams of white powder, which was found to be 
4-MAR. Moreover, according to the forensic examination the 
4-MAR was illicitly produced at the site. While not related to 
(4)  Piperonyl methyl ketone, or 3,4-methylenedioxyphenylpropan-2-one.
4,4′-DMAR, this case would suggest that the capability to 
manufacture 4,4′-DMAR may exist within drug-producing 
criminal groups within the European Union. 
3.2.2. Information provided to the EMCDDA
The EMCDDA received responses from the 28 Member States, 
Turkey and Norway. Of these, seven Member States (Denmark, 
Finland, Hungary, the Netherlands, Romania, Sweden and the 
United Kingdom) reported detections of 4,4′-DMAR (5).
Seizures
Seven Member States (Denmark, Finland, Hungary, the 
Netherlands, Romania, Sweden and the United Kingdom) 
reported seizures of 4,4′-DMAR.
4,4′-DMAR has typically been seized as powders or tablets. In 
most cases, 4,4′-DMAR was reported as the only active 
substance; in about 20 % of detections it was found in 
combination with other substances. Hungary reported the 
majority of seizures (78 cases). While the remaining Member 
States reported a small number of seizures, it is worth noting 
that in the case of the Netherlands these totalled more than 
260 kg of powder. Sweden and Denmark reported that 
4,4′-DMAR was detected in seizures of pink/red/purple 
octagonal tablets bearing the markings ‘ST’ on one side and 
‘60’ on the other. According to user websites, the ‘ST’ refers to 
‘Serotoni’ and ‘60’ refers to a 60 mg dose.
Denmark reported a seizure by customs of two purple 
octagonal tablets bearing the markings ‘ST/60’ in May 2013.
Finland reported a seizure by customs of two red tablets in 
May 2013. 
Hungary reported a total of 78 seizures, which were made by 
police between June and October 2013. 4,4′-DMAR was 
seized as tablets (41 seizures) and in powder form (37 
seizures). The quantities of tablets seized ranged from a single 
tablet to 900 tablets, with three seizures above 100 tablets 
and a total of 1 852 tablets seized. The quantities of powder 
seized ranged from 0.01 g to 193 g, with 27 seizures below 1 g 
and a total weight of 337 g seized. In most cases, 4,4′-DMAR 
was reported as the only active substance; in about 20 % of 
detections it was found in combination with other substances 
(predominantly stimulants), including pentedrone (eight cases, 
(5)  ‘Detections’ is an all-encompassing term and may include seizures and/or 
collected and/or biological samples. Seizure means a substance available 
(seized) through law enforcement activities (police, customs, border guards, 
etc.). Collected samples are those that are actively collected by drug 
monitoring systems (such as test purchases) for monitoring and research 
purposes. Biological samples are those collected from human body fluids 
(urine, blood, etc.) and/or specimens (tissues, hair, etc.).
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two of which also contained PVP or alpha-PVP) and 
mephedrone (one case), RH-34 (two cases), 5-APDB (one 
case), bk-MPA (one case), ethylphenidate (one case), the 
synthetic cannabinoid receptor agonist UR-144 (one case) and 
the common cutting agent creatine monohydrate (one case). 
In a separate case, 4,4′-DMAR was found in combination with 
four cathinones (methcathinone, MPPP, pentedrone and 
alpha-PVP). No quantitative analyses were available.
The Netherlands reported the first seizure of 4,4′-DMAR in 
November 2012 — the Dutch customs seized 500 g of white 
powder on 19 November. It was noted that the seizure had 
arrived from India. This seizure formed the basis of the first 
notification of detection of 4,4′-DMAR in the European Union 
(see section 3.6). During 2013 customs authorities in the 
Netherlands detected a further 260 kg of 4,4′-DMAR; further 
details are awaited regarding these cases.
Romania reported 13 seizures made by the police in 2013 
– as tablets (one case of five tablets) and in powder form 
(12 cases amounting to a total of 558.84 g). 
Sweden reported two seizures made by customs between 
June and December 2013 — a seizure of 10 g of white powder, 
and a seizure of two (red or red/pink) octagonal tablets bearing 
the markings ‘ST’ on one side and ‘60’ on the other.
The United Kingdom reported four seizures made by police in 
Northern Ireland, amounting to 447 tablets. In addition, five 
plastic bags containing white powder (a total amount of 
approximately 1.2 g) were recovered by police in Scotland in 
April 2014 during the investigation of a death related to 
4,4′-DMAR.
Biological samples
Two Member States (Hungary and the United Kingdom) 
reported detections of 4,4′-DMAR in biological samples. 
Twenty-seven deaths (eight in Hungary; 19 in the United 
Kingdom) were reported. Further details are provided in 
section 3.4.1 and Annex 2. Hungary also reported the 
detection of 4,4′-DMAR in biological samples taken in 
18 criminal cases related to the consumption of narcotics.
Collected samples
The United Kingdom reported the detection of 4,4′-DMAR in a 
collected sample. The sample was purchased for GBP 60 
(EUR 73) from an Internet retailer (https://www.chems-direct.
org) in March 2014. The product was a white powder and 
labelled ‘5 g’ ‘4,4-DMAR’ (Annex 1). The cis-racemate of 
4,4′-DMAR was confirmed by NMR and was further 
characterised. No other substances were reported to be 
present.
I 3.3.  Information on the involvement of organised crime in the manufacture or trafficking of the new psychoactive substance — Article 5.2(c) of the Council Decision
Limited information has been provided by Member States in 
relation to the involvement of organised crime in the 
manufacture or trafficking of 4,4′-DMAR.
According to the Hungarian authorities, organised crime 
groups are involved in the trafficking and distribution of 
4,4′-DMAR; no other details were provided.
The information about the small-scale production of the 
related substance 4-MAR in the Netherlands in 2009 would 
suggest that the capability to manufacture 4,4′-DMAR may 
exist within drug-producing criminal groups in the European 
Union. 
Money laundering aspects
No information was received on money laundering connected 
to the production and/or trafficking of 4,4′-DMAR.
Violence in connection with production, wholesale and 
distribution
No information was received on incidents of violence in 
connection with the production, wholesale and/or trafficking 
of 4,4′-DMAR.
I 3.4.  A first indication of the risks associated with the new psychoactive substance, including the health and social risks, and of the characteristics of users — Article 5.2(d) of the Council Decision
3.4.1. First indication of health risks
No non-fatal intoxications associated with 4,4′-DMAR were 
reported by the Member States. A total of 27 deaths 
associated with 4,4′-DMAR were reported by Hungary (eight 
deaths) and the United Kingdom (19 deaths). The deaths in 
Hungary occurred between June and October 2013 and those 
in the United Kingdom between June 2013 and February 2014. 
The cause of death has not yet been reported for any of the 
deaths. Annex 2 provides the available details on these deaths.
Data on gender and age were available for 26 of the 
decedents. Nineteen were male (four from Hungary; 15 from 
the United Kingdom); seven were female (four from Hungary; 
three from the United Kingdom). They were aged between 
16 and 43 years.
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4,4′-DMAR was detected in post-mortem biological samples in 
all of the 27 deaths. 4,4′-DMAR was quantified in 23 of the 
deaths, with concentrations ranging from less than 0.02 mg/L 
to 3.75 mg/L in blood, and from 5.93 mg/L to 32.95 mg/L in 
urine. In all of the 27 deaths, one or more psychoactive 
substances (and/or their metabolites) were detected in 
post-mortem biological samples in addition to 4,4′-DMAR 
(Annex 2).
Pharmacology
One study, which the authors provided to the EMCDDA ahead 
of print, has examined the pharmacology of 4,4′-DMAR. The 
study examined the effects of (±)-cis-4,4′-DMAR in vitro on 
effecting release of dopamine, noradrenaline and serotonin at 
the dopamine transporter (DAT), noradrenaline transporter 
(NET) and serotonin transporter (SERT), respectively, using 
rat brain synaptosomes. The effects of (±)-cis-4,4′-DMAR were 
compared with d-amphetamine, aminorex and (±)-cis-4-MAR.
The dose-response effects of d-amphetamine, aminorex, 
(±)-cis-4-MAR and (±)-cis-4,4′-DMAR on release at DAT, NET 
and SERT are shown in Figure 2. Potency values (expressed 
as half maximal effective concentrations, EC
50
) for the test 
substances based on data from Figure 2 are provided in Table 
1. All four test substances displayed potent releasing activity 
at DAT, with EC
50
 values ranging from 1.7 ± 0.2 nM for (±)-cis-
4-MAR to 9.1 ± 0.9 nM for aminorex. The drugs also showed 
considerable potency at NET, with EC
50
 values ranging from 
4.8 ± 0.9 nM for (±)-cis-4-MAR to 26.9 ± 5.9 nM for (±)-cis-
4,4′-DMAR. Activity at SERT varied more than 100-fold across 
the four substances, with (±)-cis-4,4′-DMAR exhibiting the 
highest potency at releasing serotonin (EC
50 
= 18.5 ± 2.8 nM). 
All test substances achieved 100 % of maximal release at DAT, 
NET and SERT. When considering the overall transporter 
selectivity of the test compounds, d-amphetamine was the 
most selective for DAT/NET over SERT, with a DAT/SERT ratio 
of 473, whereas (±)-cis-4,4′-DMAR was essentially non-
selective with a DAT/SERT ratio of 2 (Table 1).
These results suggest that (±)-cis-4,4′-DMAR is a potent 
efficacious releaser at DAT, NET and SERT in rat brain tissue. 
The potency of (±)-cis-4,4′-DMAR at DAT and NET is similar to 
that of d-amphetamine and aminorex. However, (±)-cis-4,4′-
DMAR exerted much more potent actions at SERT when 
compared to d-amphetamine, aminorex and (±)-cis-4-MAR 
(Brandt et al., 2014).
No studies were identified in the literature that have examined 
the pharmacology of (±)-trans-4,4′-DMAR.
FIGURE 2
Dose-response effects of d-amphetamine, aminorex, (±)-cis-4-MAR and (±)-cis-4,4′-DMAR in evoking release from DAT, NET 
and SERT in rat brain synaptosomes. (±)-cis-4,4′-DMAR elicited potent release of dopamine, noradrenaline and serotonin.
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TABLE 1
Stimulation of release at DAT, NET and SERT in rat brain 
synaptosomes (Brandt et al., 2014).
Substance
Release at 
DAT
EC
50
 (nM)a
Release at 
NET
EC
50
 (nM)a
Release at 
SERT
EC
50
 (nM)a
DAT/ 
SERT 
ratiob
d-Amphetamine 5.5 ± 0.5 8.2 ± 1.6 2602 ± 
494
473
Aminorex 9.1 ± 0.9 15.1 ± 3.5 414 ± 78 45
(±)-cis-4-MAR 1.7 ± 0.2 4.8 ± 0.9 53.2 ± 6.8 31
(±)-cis-4,4′-DMAR 8.6 ± 1.1 26.9 ± 5.9 18.5 ± 2.8 2
a  Data are expressed as mean ± SD for n = 3–4 experiments performed in 
triplicate.
b  DAT/SERT ratio calculated by (EC
50
 at DAT)-1/ (EC
50
 at SERT)-1; higher value 
indicates greater DAT selectivity.
Toxicology
No studies were identified in the literature that have examined 
the toxicology of 4,4′-DMAR. No clinical case reports related to 
4,4′-DMAR toxicity were identified in the literature. 
The available information from the 27 deaths reported by 
Hungary and the United Kingdom is provided in Annex 2. There 
is insufficient information currently available to characterise 
the toxidrome related to 4,4′-DMAR exposure.
As discussed above, (±)-cis-4,4′-DMAR has been shown in 
vitro to be a potent substrate-type releaser at DAT, NET, and 
SERT (Brandt et al., 2014). Based on these data, one 
hypothesis that requires testing is that (±)-cis-4,4′-DMAR 
exposure also leads to high levels of extracellular monoamines 
in vivo. Should this be the case, it may explain some of the 
toxicological features and findings noted in the deaths 
reported by Hungary and the United Kingdom. In addition, it 
would also be important to consider potential interactions 
with other pharmacologically active substances, particularly 
those that affect the monoaminergic system (Brandt et al., 
2014); in this respect it is important to note that in the majority 
of deaths reported, one or more substances (or their 
metabolites) known to affect the monoaminergic system 
— such as cocaine, MDMA, amphetamine — were also 
detected post-mortem (Annex 2).
Abuse liability and dependence potential
No studies were identified in the literature that have examined 
the abuse liability and dependence potential of 4,4′-DMAR.
3.4.2. Characteristics of users
No studies were identified that examined the characteristics 
of users of 4,4′-DMAR. The section below includes a 
discussion of the characteristics of users, which includes 
information from the Member States and self-reported 
experiences on user websites. Regarding information from 
user websites, it is important to note that it is not possible to 
confirm the specific substance(s) used, nor the purity, dose, 
etc. In addition, analysis of products containing new 
psychoactive substances that are sold on the drug market has 
shown that the composition can differ between that claimed 
by the retailer, and over different geographical areas and time. 
Information from seizures, the collected sample, EMCDDA 
monitoring of Internet suppliers/retailers, and user websites 
suggests that 4,4′-DMAR has been sold both as a drug in its 
own right and in tablet forms with a similar appearance to 
‘ecstasy’ tablets. In the latter case, users may be unaware that 
they are using 4,4′-DMAR. 
Route of administration, dose and drug regimens
Information provided by the Member States and from user 
websites suggests that the routes of administration for 
4,4′-DMAR include nasal insufflation and oral (including 
consumption of tablets and ‘bombing’, the practice of 
wrapping powder in cigarette paper and swallowing) 
(chemsrus.com, 2014; drugs-forum.com, 2014; serotonin.info, 
2014; ukchemicalresearch.org, 2014). In one of the death 
cases reported by Hungary, the route of administration of 
4,4′-DMAR was by injection. The physical forms detected in 
seizures would appear to be consistent with these routes of 
administration.
Information from user websites, while limited, suggests that a 
range of ‘doses’ are used. ‘Low doses’ were reported as 
10–15 mg insufflated or 10–25 mg oral with a ‘high oral dose’ 
being reported as 120 mg (drugs-forum.com, 2014). Another 
site reported the ‘dosage’ (not further described) as 30–
100 mg (serotoni.info, 2014). Oral ‘doses’ between 60 and 
200 mg and 65 mg insufflated have also been mentioned 
(ukchemicalresearch.org, 2014; chemsrus.com, 2014).
Information from user websites suggests that 4,4′-DMAR may 
be used on its own or in combination with other new 
psychoactive substances and/or controlled drugs (drugs-
forum.com, 2014). In all of the 27 deaths reported by the 
Member States and in 12 of the 18 biological samples 
reported by Hungary related to the consumption of narcotics, 
one or more new psychoactive substances and/or controlled 
drugs (and/or their metabolites) were detected post-mortem 
(Annex 2). 
Subjective effects
No studies were identified that have examined the subjective 
effects of 4,4′-DMAR in humans; information is limited to that 
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provided in a very small number of self-reported experiences 
from user websites. Onset is described as being fast, within 
10 to 60 minutes, with effects lasting several hours 
(ukchemicalresearch.org, 2014; drugs-forum.com, 2014). 
Subjective effects appear to be those related to stimulant-type 
drugs. One user who reported having taken alcohol and an 
unspecified ‘triple re-uptake inhibitor’ prior to using 4,4′-DMAR 
noted increased heart rate, increased body temperature, jaw 
clenching, facial spasms, sweating, stimulation, psychosis and 
hallucinations (ukchemicalresearch.org, 2014). Another report 
described a similarity to the effects of MDMA, noting ‘an 
extremely long stimulated comedown’ (chemsrus.com, 2014). 
This is mirrored by a comment that ‘the hallmark of this drug is 
its long half-life’ (drugs-forum.com, 2014).
Availability, supply and price
EMCDDA monitoring in May 2014 of Internet retailers selling 
4,4′-DMAR identified two retailers that were selling the 
substance. The first site marketed 4,4′-DMAR as a ‘research 
chemical’. It was advertised in powder form only, with 
quantities ranging from 500 mg (EUR 18.10) to 100 g 
(EUR 220). All quantities above 500 mg appeared to be 
offered with large price discounts ranging from 55–80 %, 
depending on the quantity purchased. This retailer was the 
same site from which the collected sample of 4,4′-DMAR was 
obtained (reported by the United Kingdom, section 3.2.2). The 
second site offered 4,4′-DMAR in powder form; further details 
including the quantities available and price were only available 
on application to the site. Four retailers were identified that 
appear to have discontinued the sale of 4,4′-DMAR; the 
reasons for this were not provided.
Seizure data reported by the Member States suggest that 
4,4′-DMAR is also sold directly on the illicit drug market as 
ecstasy; no information was reported on the price of 4,4′-
DMAR when sold as ecstasy.
Prevalence of use
No prevalence surveys were identified that have examined the 
use of 4,4′-DMAR in the general population or in targeted 
populations. Information from seizures and deaths reported by 
the Member States suggests that in some cases 4,4′-DMAR is 
sold as ecstasy, although the extent of this practice is unknown.
I 3.5.  Information on whether or not the new substance is currently under assessment, or has been under assessment, by the UN system — Article 5.2(e) of the Council Decision
The World Health Organization is the specialised United 
Nations agency designated for the evaluation of the medical, 
scientific and public health aspects of psychoactive 
substances under the 1961 Single Convention on Narcotic 
Drugs and the 1971 Convention on Psychotropic Substances. 
On 5 March 2014 the World Health Organization informed the 
EMCDDA that para-methyl-4-methylaminorex (i.e. 4,4′-DMAR) 
is currently not under assessment and has not been under 
assessment by the United Nations system.
I 3.6.  The date of notification on the Reporting Form of the new psychoactive substance to the EMCDDA or to Europol — Article 5.2(f) of the Council Decision
The first official notification to the EMCDDA of 4,4′-DMAR 
dates from 10 December 2012 from the Netherlands national 
focal point. The Reporting Form details a seizure of 500 g of 
white powder on 19 November 2012 by customs authorities at 
Amsterdam. The importation was noted to have arrived from 
India. The identification was based on the analytical 
techniques of NMR (6) and GC-MS (7), and it was also noted 
that this substance partly decomposes under certain 
conditions when using GC-MS.
4,4′-DMAR was added to the list of new psychoactive 
substances monitored by the EMCDDA and Europol through 
the Early Warning System and a profile of the substance was 
created in the EMCDDA European Database on New Drugs 
(EDND). Since then analytical details, background information 
and public health alerts have been exchanged between 
EMCDDA, Europol and the Member States on an ad hoc basis. 
The Commission and the EMA were kept duly informed.
I 3.7.  Information on whether or not the new psychoactive substance is already subject to control measures at national level in a Member State — Article 5.2(g) of the Council Decision
Hungary reported that 4,4′-DMAR is subject to control 
measures under drug control legislation. It is specifically 
named in Schedule C of Government Decree 66/2012 (added 
by ‘256/2013 (July 5) Government Regulation § 17, Annex 9’, 
effective 15 July 2013).
In Poland, 4,4′-DMAR falls under the definition of a 
‘substitution drug’ under the Act amending the Act on 
Counteracting Drug Addiction and the Act on State Sanitary 
Inspection, 2010 and as such its marketing and production is 
penalised with a fine. 
(6)  Nuclear magnetic resonance spectroscopy.
(7)  Gas chromatography-mass spectroscopy.
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Finland and Norway reported that 4,4′-DMAR is subject to 
control measures under medicines legislation. In Finland it has 
been controlled since 12 March 2014 under the Medicines Act 
(395/87). 
Spain reported that ‘although there is no current specific 
legislation, to our knowledge, controlling production, 
commerce, imports, exports or use/consumption of this 
substance and given that it may cause harmful effects to 
those using it, the same way as illegal drugs do, there is 
generic legislation (administrative and criminal) on health 
protection which is fully applicable, if necessary’.
Twenty-four Member States (Austria, Belgium, Bulgaria, 
Croatia, Cyprus, the Czech Republic, Denmark, Estonia, 
France, Germany, Greece, Ireland, Italy, Latvia, Lithuania, 
Luxembourg, Malta, the Netherlands, Portugal, Romania, 
Slovakia, Slovenia, Sweden and the United Kingdom) and 
Turkey reported that 4,4′-DMAR is not subject to control 
measures at the national level.
I 3.8.  Further information — Article 5.2(h) of the Council Decision
3.8.1.  The chemical precursors that are known to have 
been used for the manufacture of the substance
No information was reported by the Member States, Turkey or 
Norway about the chemical precursors or manufacturing 
methods used to make the 4,4′-DMAR that has been detected 
on the drug market. 
Methods for the production of 4,4′-DMAR are documented in 
the literature. One such method describes the production of 
4,4′-DMAR in five reaction steps using 
4’-methylpropiophenone as the precursor. 
4’-methylpropiophenone appears to be readily available from 
chemical suppliers. The 4’-methylpropiophenone precursor is 
first α-brominated, then the resulting alpha-bromo ketone 
intermediate is reacted with sodium diformylamide to give the 
N,N-diformamide derivative. Hydrolysis of this under acidic 
conditions provides access to the primary amine intermediate 
4-methylcathinone which, following its reduction to 
4-methylnorephedrine, can be converted to either (±)-cis-4,4′-
DMAR via cyanogen bromide or (±)-trans-4,4′-DMAR via 
potassium cyanate. In addition, it is noted that the synthesis of 
4,4’- DMAR shares a number of steps that are also employed 
for the synthesis of cathinone derivatives (Brandt et al., 2014). 
3.8.2.  The mode and scope of the established or 
expected use of the new substance
No studies were identified that have examined the mode and 
scope of established or expected use of 4,4′-DMAR. Given the 
limited information currently available, the relevant 
information reported by the Member States has been included 
in the previous sections. It is important to note in this respect 
that information from seizures and deaths suggest that 
4,4′-DMAR may be sold as ecstasy directly on the illicit drug 
market.
Settings of use
No studies were identified that have examined the settings of 
use of 4,4′-DMAR. Information from the deaths reported by the 
Member States suggests that 4,4′-DMAR may be used in a 
range of settings (Annex 2).
3.8.3.  Other use of the new psychoactive substance 
and the extent of such use, the risks associated 
with this use of the new psychoactive substance, 
including the health and social risks
No information was provided by the Member States, Turkey or 
Norway that indicated that 4,4′-DMAR had any other use apart 
from in analytical reference materials and in legitimate 
scientific research into its chemistry, pharmacology and 
toxicology as a result of its emergence on the drug market.
From the available information it does not appear that 
4,4′-DMAR is used in the manufacture of a medicinal product 
in the European Union. However, the collection of information 
cannot be considered exhaustive in the absence of a 
European Union database on the synthetic routes of all 
medicinal products (8).
I 4.  Information from the EMA as requested by Article 5.3 of the Council Decision
I 4.1. Marketing authorisation
Twenty-one Member States, Iceland and Norway responded to 
the EMA’s information request (section 2). They reported that 
the new psychoactive substance 4,4′-DMAR has not obtained 
(8)  I.e. products that have been granted a marketing authorisation, or where an 
application for a marketing authorisation has been made, or where the 
marketing authorisation has been suspended.
JOINT REPORTS I 4,4′-DMAR
12 / 20
a marketing authorisation (9). The EMA also reported that the 
new psychoactive substance 4,4′-DMAR has not obtained a 
marketing authorisation through the central authorisation 
procedure.
I 4.2. Application for a marketing authorisation
Twenty-one Member States, Iceland and Norway responded to 
the EMA’s information request (section 2). They reported that 
the new psychoactive substance 4,4′-DMAR is not the subject 
of an application for a marketing authorisation (9). The EMA 
also reported that the new psychoactive substance 4,4′-DMAR 
is not the subject of an application for a marketing 
authorisation through the central authorisation procedure.
I 4.3. Suspended marketing authorisation
Twenty-one Member States, Iceland and Norway responded to 
the EMA’s information request (section 2). They reported that 
there had been no cases of a suspended marketing 
authorisation that had been granted in respect of the new 
psychoactive substance 4,4′-DMAR (9). The EMA also reported 
that the new psychoactive substance 4,4′-DMAR is not the 
subject of a suspended marketing authorisation through the 
central authorisation procedure.
I 5. Conclusion
4,4′-DMAR is a di-substituted 2-amino-5-phenyl oxazoline 
substance that appears to have stimulant properties. It is a 
derivative of aminorex and 4-methylaminorex, both synthetic 
stimulants that are controlled under the 1971 United Nations 
Convention on Psychotropic Substances. 
An in vitro study has shown that (±)-cis-4,4′-DMAR is a potent, 
efficacious substrate-type releaser at transporters for 
dopamine, norepinephrine and serotonin.
(9)  Austria, the Croatia, Czech Republic, Denmark, Estonia, Finland, Germany, 
Hungary, Iceland, Ireland, the Netherlands, Norway, Portugal, Slovenia, Spain, 
Sweden and the United Kingdom provided responses in relation to both 
human and veterinary medicinal products. Italy and Lithuania provided 
responses in relation to human medicinal products. Belgium, France, Latvia 
and Poland provided responses in relation to veterinary medicinal products. In 
addition, the EMA provided information in relation to both human and 
veterinary medicinal products in respect of the central authorisation 
procedure.
4,4′-DMAR has been available on the European Union drug 
market since at least November 2012 and has been detected 
in seven Member States. One Member State has reported 
large powder seizures (>260 kg) by its customs authorities. It 
has been detected in tablets, some of which have markings 
resembling ecstasy tablets’ markings, and in powder form. It 
appears that its availability from Internet retailers has 
decreased in recent months.
One Member State has reported the production of tablets, and 
that organised crime groups are involved in the trafficking and 
distribution of 4,4′-DMAR. A precursor that may be used for 
the production of 4,4′-DMAR appears to be readily available 
from chemical suppliers.
Twenty-seven deaths have been reported in two Member 
States with analytical confirmation of 4,4′-DMAR in post 
mortem samples; at least one other substance was present in 
each of these cases. On this basis, the potential impact from 
the further spread of 4,4′-DMAR on public health is a key 
concern. 
We conclude that the health and social risks caused by the 
manufacture, trafficking and use of 4,4′-DMAR, and the 
involvement of organised crime and possible consequences of 
control measures, could be thoroughly assessed through a 
risk assessment procedure in accordance with Article 6 of 
Council Decision 2005/387/JHA.
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I  Annex 1 Images of 4,4’-DMAR from seizures and collected samples
Country Image Description
Hungary
 
 
 
Seizures: 2013
Sweden Seizure: 6 December 2013
Tablets, seized in Stockholm
Seizing authority: customs
United Kingdom
 
Seizures: between June and August 2013
Tablets, seized in Northern Ireland
Seizing authority: police
Collected sample: March 2014
White powder
Collecting authority: School of Pharmacy and 
Biomolecular Sciences (Liverpool John Moores 
University) and ROAR Forensics (Malvern).
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I  Annex 2 Deaths associated with 4,4′-DMAR reported by Hungary and the United Kingdom
Case MS
Date  
of death
Age Sex Matrix
4,4′-DMAR 
concentration 
Other substances detected and 
concentration (where available)
Adverse events/autopsy findings Additional information reported
1 HU Jun 2013 25 M Bloodf
Urine
1.158 mg/L
43.493 mg/L
7-Amino-clonazepam 0.1405 mg/L 
alpha-PVP 0.0056 mg/L 
Pentedrone 0.0274 mg/L
7-Amino-clonazepam 0.0961 mg/L 
alpha-PVP 0.0908 mg/L 
Clonazepam 0.0137 mg/L 
4-MEC 6.522 mg/L 
Pentedrone 15.276 mg/L
High body temperature, extensive 
bleeding in the muscles.
No information on route of administration, 
however ‘there was no pin-prick’.
2 HU Jun 2013 25 F Bloodf 0.0427 mg/L Amphetamine 0.4918 mg/L 
alpha-PVP 0.2357 mg/L 
Midazolam 0.2374 mg/L
High body temperature, extensive 
bleeding in the muscles and organs. 
Confusion, disorientation, 
unconsciousness, perspiration.
Injected, use about 3 pm, 12 hours later 
died in the hospital.
3 HU Jun 2013 18 M Bloodu + (no quantitation) Mephedrone (no quantitation) 
MDMA (no quantitation) 
Pentedrone (no quantitation)
Myoclonus, unconsciousness, body 
temperature: 42.9°C, internal bleeding 
(oral, intestinal), cardial and 
respiratorical arrest. Autopsy: large 
brain oedema, diffuse internal 
bleeding, bleeding in lungs, dilatation 
of the right ventricle and atrium. 
Went out, did not go home. His parents 
found him on the street, in poor condition. 
Ambulance took him to the hospital, next 
morning died.
4 HU Aug 2013 43 F Bloodf
Urine
2.055 mg/L
5.928 mg/L
Mephedrone 0.5723 mg/L 
alpha-PVP 0.014 mg/L 
Alprazolam 0.1124 mg/L
Mephedrone 0.3215 mg/L 
alpha-PVP 0.0056 mg/L 
Alprazolam 0.0534 mg/L 
OH-Alprazolam 0.027 mg/L
— She was found at home. She had died 2–3 
days before. No information on route of 
administration; however, ‘there was no 
pin-prick’.
5 HU Sep 2013 20 F Bloodf
Urine
3.565 mg/L
32.945 mg/L
Alprazolam 0.0951 mg/L 
alpha-PVP 0.0296 mg/L 
Pentedrone 0.1730 mg/L 
THC-COOH 0.0127 mg/L
Pentedrone 44.544 mg/L 
Amphetamine 0.353 mg/L 
alpha-PVP 0.0844 mg/L 
Alprazolam 0.0167 mg/L
— She died after a party. No information on 
route of administration; however, ‘there was 
no pin-prick’.
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Case MS
Date  
of death
Age Sex Matrix
4,4′-DMAR 
concentration 
Other substances detected and 
concentration (where available)
Adverse events/autopsy findings Additional information reported
6 HU Oct 2013 18 F Bloodu + (no quantitation) MDA 0.0251 mg/L 
MDMA 0.1989 mg/L
Agitation, sweat, pale. 41.2°C 
temperature, glucose 1.7 mmol/l. 
Autopsy: brain oedema, bleeding and 
oedema in the lungs, ‘shock’ kidneys.
She consumed drugs with her friend in the 
afternoon. Parents took her to the hospital, 
after 1 hour she died (arrived: 23:05, died: 
00:04).
7 HU Oct 2013 27 M Bloodu
Urine
+ (no quantitation)
+ (no quantitation)
MDA 0.04 mg/L 
MDMA 0.8863 mg/L 
Mephedrone 0.0363 mg/L
MDA (no quantitation) 
MDMA (no quantitation) 
Mephedrone (no quantitation)
Mild brain oedema, shock, in the heart 
right atrial and ventricular dilatation, 
intestinal bleeding.
He consumed drugs with his friends at 
18:30, died next morning.
8 HU Oct 2013 37 M Bloodu + (concentration to 
be confirmed)
MDA (concentration to be confirmed) 
MDMA (concentration to be 
confirmed)
Autopsy: cardiomyopathy, brain 
edema, pulmonary edema, tonsillar 
herniation, emollient brain tissue.
—
9 UK Jun 2013 36 M Bloodf 0.66 mg/L Benzoylecognine 0.97 mg/L 
Cocaine <0.05 mg/L 
Codeine <0.02 mg/L 
Tetra/levamisole (unconfirmed)
— —
10 UK Jun 2013 25 M Bloodf 0.9 mg/L 4-MEC 0.05 mg/L 
MDMA 0.82 mg/L 
MDA 
PMMA 0.11 mg/L 
PMA 
THC-COOH
— Drinking heavily, took ‘methadrone’, 
continued drinking, took 2 ‘ecstasy’ tabs 
immediately felt unwell, agitated. 
Unresponsive 1 hr later.
11 UK Jun 2013 33 M Bloodf 0.28 mg/L Benzoylecognine 0.04 mg/L — Believed to have taken ‘cocaine and 
ecstasy’. Deceased had taken ‘speckled 
cherries tablets’ orally. Cerebral oedema at 
post mortem, suspected to have taken 
drugs at 14:30, found unconscious the 
following day at 07:30, died in hospital the 
day after at 10:30.
12 UK Jun 2013 27 M Bloodf 0.7 mg/L Benzoylecognine 0.36 mg/L 
MDMA 0.19 mg/L 
MDA 
Mirtazapine (a low level) 
Indications of low level of cocaine
— 4,4′-DMAR detected on nasal swabs with 
cocaine. Found dead on arrival of 
ambulance service, tablets and powder 
found when house searched.
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Case MS
Date  
of death
Age Sex Matrix
4,4′-DMAR 
concentration 
Other substances detected and 
concentration (where available)
Adverse events/autopsy findings Additional information reported
13 UK Jul 2013 29 M Bloodf <0.02 mg/L PMA 0.09 mg/L 
Diazepam plus metabolite 0.14 mg/L 
THC-COOH 
Indications of lidocaine
He appeared ‘wiped out’, was agitated 
and overheating, began foaming at 
mouth.
Friend purchased 10 x speckled cherries for 
£50, two weeks prior, from an unknown 
male in a bar. Socialising with friends at his 
flat drinking alcohol, taking ‘E’ ‘speckled 
cherry’, witness describes him taking 3 x 
‘speckled cherry’ E tabs over the course of 
the evening.
14 UK Jul 2013 40 M Bloodf 1.25 mg/L MDMA 0.02 mg/L 
Diazepam 0.05 mg/L 
THC-COOH
— Consumed alcohol, ecstasy and cannabis, 
found dead the next day, nothing at post 
mortem.
15 UK Aug 2013 41 M Bloodf 3.13 mg/L MDMA 0.3 mg/L  
MDA 
Citalopram 0.42 mg/L 
Epileptic type seizure prior to death. Deceased had taken ‘speckled cherries 
tablets’. Alcoholic, heavy intake prior to 
death, epileptic type seizure prior to death, 
tablets at scene.
16 UK Aug 2013 18 F Bloodf 2.1 mg/L bk-MDMA 0.84 mg/L  
4-MEC 0.72 mg/L 
FMC 
THC-COOH (low level)
— Deceased had taken ‘speckled cherries 
tablets’. Died at home following a house 
party (same location) after consuming an 
unknown quantity of ecstasy tablets and 
‘meth’, tablets described as grey with cherry 
logo, witnesses speculate she consumed 
2–3 tablets.
17 UK Aug 2013 19 F Bloodf
Bloodu 
(ante 
mortem)
~0.85 mg/L
1.8 mg/L
4-MMC ~0.045 mg/L
4-MMC <0.01 mg/L 
4-MEC <0.01 mg/L 
bk-MDMA <0.01 mg/L
— Collapsed at a party, suspected overdose, 
taken to hospital unconscious and later 
died. Witnesses described her ‘consuming 
ecstasy and snorting meth’.
18 UK Aug 2013 20 M Bloodf 1.6 mg/L 4-MEC 1.68 mg/L 
bk-MDMA 0.26 mg/L 
4-MMC (low level) 
Diazepam (low level) 
THC-COOH 
Indications FMC
Suffered seizure. Deceased had taken ‘speckled cross tablet’. 
Suffered seizure and died, unidentified 
tablets and 9.36 g of powder was seized at 
the scene. Powder contained 4-MEC, 
bk-MDMA, fmc? (no quantification). Unclear 
if this powder was linked to the deceased as 
more than one person was present in the 
house. 4,4′-DMAR and 4-MMC detected on 
nasal swabs taken post-mortem.
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Case MS
Date  
of death
Age Sex Matrix
4,4′-DMAR 
concentration 
Other substances detected and 
concentration (where available)
Adverse events/autopsy findings Additional information reported
19 UK Sep 2013 21 M Bloodf 0.21 mg/L 4-MMC 0.02 mg/L 
4-MEC 0.1 mg/L 
bk-MDMA 0.07 mg/L 
Diazepam 0.03 mg/L 
THC-COOH 
Amiodarone
Agitated state, sweating profusely, 
and had problems breathing.
Alcohol, one or two ecstasy tablets, 
speckled cherry possibly green, 
‘methadrone’ had been consumed. Taken to 
hospital (arrived 18:57), after taking ill at a 
house party. Agitated state, sweating 
profusely, and had problems breathing, 
deteriorated rapidly, pronounced dead 
23:10. Had been partying for the previous 
two/three days. 
20 UK Sep 2013 31 M Bloodf 1.72 mg/L Benzoylecognine 0.55 mg/L 
Indications of low levels of cocaine 
and desmethyldiazepam
Cardiac arrest. Drinking and taking drugs (ecstasy and 
cocaine, 4 x ‘blue’) in his home with two 
friends in the morning, became unwell at 
11.00, unresponsive when paramedics 
attended, taken to hospital, suffered cardiac 
arrest, and died at 12:24. Two witnesses 
also admitted to hospital, one said they had 
all taken drugs and deceased had taken 4 
‘blues’ in one go. 
21 UK Nov 2013 21 M Bloodf 1.75 mg/L bk-MDMA 0.14 mg/L 
4-MEC 0.06 mg/L 
4-MMC 0.04 mg/L 
THC-COOH
18.00: sweating, paranoid thoughts; 
midnight: sweating profusely, 
convulsion, cardiac arrest.
No previous history of drug abuse. Thought 
to have taken e tabs. Mirtazapine 
prescribed, atropine and adrenaline 
administered.
22 UK Nov 2013 16 F Bloodf 1.1 mg/L Indications of diazepam (low level 
Lidocaine 
Amiodarone 
Methylprednisolone?
Cardiac arrest. Cardiac arrest while out with friends. PMH 
asthma.
23 UK Dec 2013 30 M Bloodf <0.02 mg/L Olanzapine 0.66 mg/L 
Diazepam plus metabolite 0.41 mg/L 
Codeine 0.13 mg/L 
Paracetamol 11.1 mg/L  
Indications of pregabalin
— History of drug misuse, overdoses and 
mental illness.
24 UK Dec 2013 33 M Bloodf 1.01 mg/L 4-MEC (low level) 
bk-MDMA 0.22 mg/L 
Diazepam plus metabolite (low level) 
THC-COOH
— Thought to have taken ‘plant food’.
25 UK Dec 2013 — — Bloodf 1.72 mg/L THC-COOH 
BAC 53 mg% 
UAC 87 mg%
— Found dead in bed, had been drinking 
heavily, history of drug abuse including 
ecstasy.
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Annex 2
Case MS
Date  
of death
Age Sex Matrix
4,4′-DMAR 
concentration 
Other substances detected and 
concentration (where available)
Adverse events/autopsy findings Additional information reported
26 UK Dec 2013 41 M Bloodf 3.75 mg/L 4-MEC 0.53 mg/L 
MDMA 0.72 mg/L 
MDA 
THC-COOH 
Quetiapine (a low level)
Shaking all over, sweating, having a fit, 
hands stuck open with fingers 
squeezing together like claws.
Call to ambulance service reported a male 
taking ecstasy and going into cardiac arrest. 
At the time of his death he was hosting a 
party, a large quantity of drugs were 
allegedly available, ‘cocaine, speckled Rolex 
ecstasy tablets, magic and cannabis’ and 
alcohol. Severe heart disease at post 
mortem.
27 UK Feb 2014 35 M Bloodf 3.5 mg/L bk-MDMA 0.33 mg/L  
4-MEC 0.16 mg/L  
FMC 0.11 mg/L 
Procyclidine 0.11 mg/L 
Diazepam 0.06 mg/L 
Desmethyldiazepam 0.09 mg/L 
THC-COOH
Fitting, unconscious and breathing. Taking ecstasy tablets and legal highs, 
‘taking cocaine and ecstasy’, ‘fitting, 
unconscious and breathing’ when 
ambulance called at approx. 03:13, police 
and ambulance arrived 03:21, deceased. 
Other person present taken to hospital 
described as critical.
Note: in all cases 4,4′-DMAR was analytically confirmed in post-mortem biological samples.  
Key: MS: Member State; HU: Hungary; UK: United Kingdom; M: male; F: female; Bloodf: femoral blood sample; Bloodu: site of blood sample unspecified; –: Not reported.
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